Pacira BioSciences Posts Record EXPAREL Sales, Eyes Asian Expansion
Event summary
- Pacira BioSciences reported Q4 2025 revenues of $196.9 million, a 5% increase year-over-year, driven by record EXPAREL sales.
- Full-year 2025 revenues reached $726.4 million, a 4% increase compared to 2024.
- The company entered into a strategic partnership with LG Chem to commercialize EXPAREL in select Asian-Pacific markets, receiving an upfront payment.
- Pacira repurchased 2.0 million shares in Q4 2025, totaling 5.9 million shares repurchased for the full year at a cost of $150 million.
The big picture
Pacira’s reliance on EXPAREL for the majority of its revenue creates a concentration risk. The partnership with LG Chem represents an attempt to diversify geographically and mitigate this risk, but success is not guaranteed. The company’s aggressive share repurchase program signals confidence in its current valuation, but also limits capital available for R&D or acquisitions.
What we're watching
- Market Penetration
- The success of the LG Chem partnership will hinge on navigating regulatory hurdles and establishing distribution networks in the Asian-Pacific region, potentially impacting Pacira’s overall growth trajectory.
- Patent Protection
- Continued patent protection for EXPAREL remains critical, as generic competition could significantly erode market share and pricing power, impacting future revenue projections.
- R&D Pipeline
- The progress and eventual commercialization of PCRX-201, Pacira’s gene therapy candidate, will be a key determinant of long-term growth and diversification beyond EXPAREL.
Related topics